Mod GRF(1-29) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
| Property | Value | Notes |
|---|---|---|
| Appearance as powder | White to off-white solid | Minor batch-to-batch variation is normal |
| Solubility class | Soluble in water and aqueous buffers | Dissolution can be slowed by aggregates |
| Typical storage temperature | Minus 20 degrees Celsius or below | Protected from light and moisture |
| Storage after reconstitution | 2 to 8 degrees Celsius, short term | Longer holding requires freezing |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity and identity confirmation |
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Many websites that allow explicit AI generated images or videos have been created, and this has been used to create illegal content, such as rape, child sexual abuse material, necrophilia, and zoophilia.
== After 1945 == After the Second World War, the BRSD was re-founded. The group in the Soviet occupation zone disintegrated after 1946. The organization in West Germany was marginialized because of the Cold War, but was able to revitalize itself after 1968. Today, the BRSD is a member of the Attac network, of Oikocredit, Kairos Europa, and the International League of Religious Socialists.
Like CMX-1152, the herbal mixture known as Protandim that supplanted it was marketed by Lifeline as an "anti-aging" supplement that increases the body's antioxidant defenses by upregulating superoxide dismutase, catalase, and glutathione peroxidase. According to the company, the product was initially sold through retail channels such as GNC; however, in 2009, after several consecutive years of multimillion-dollar losses, the company, which by then was doing business under the name LifeVantage, stopped marketing it through retailers and switched to multi-level marketing, selling it instead through a network of commissioned independent distributors. According to LifeVantage, the move from retail to multi-level marketing was prompted by the January 2008 hiring of David W. Brown, (formerly CEO and president of Metabolife) as the company's CEO and president. Beginning in 2005, Protandim was produced under a manufacturing agreement with The Chemins Company of Colorado Springs, Colorado. In July 2008, LifeVantage entered into a new manufacturing agreement with Cornerstone Research & Development to produce Protandim, and with Wasatch Product Development to produce a Protandim-based skin cream (TrueScience). In 2006, biochemist Joe M. McCord joined the LifeVantage board of directors as the company's director of science. McCord, who is listed by the U.S. Securities and Exchange Commission as a LifeVantage insider shareholder, served as a spokesperson for Protandim and was responsible for distributor training and product research.
Naram-Sin was a son of Manishtushu. He was thus a nephew of King Rimush and grandson of Sargon and Tashlultum. Naram-Sin's aunt was the High Priestess Enheduanna. Most recensions of the Sumerian King List show him following Manishtushu but the Ur III version of the king list inverts the order of Rimush and Manishtushu. To be fully correct, rather than Naram-Sin or Naram-Suen "in Old Akkadian, the name in question should rather be reconstructed as Naram-Suyin (more precisely, /narām-tsuyin/) or Naram-Suʾin (/narām-tsuʾin/)".
== External links == "Discrimination des femmes à l'embauche" [Discrimination against women in hiring] (in French). Archived from the original on March 28, 2007. "Hommes et femmes" [Men and women]. Observatoire des Inégalités (in French). Archived from the original on February 19, 2007. "Lutte contre les discriminations et promotion de l'égalité" [Fighting discrimination and promoting equality]. Defenseurs des droits (in French). Archived from the original on June 13, 2017. "La discrimination des femmes : un sujet d'actualité" [Discrimination against women: a topical issue]. CentrOjeunes (in French). December 6, 2012. Archived from the original on August 8, 2016. "Discrimination des femmes à l'embauche" [Discrimination against women in hiring] (in French). Archived from the original on March 28, 2007. "Haut conseil à l'égalité des droits" [High Council for Equal Rights]. Haut Conseil a L'égalité entre les femmes et les hommes (in French). Archived from the original on May 22, 2013. "Secrétariat d'état chargé de l'égalité entre femmes et hommes et de la lutte contre les discriminations" [State Secretariat for Gender Equality and Anti-Discrimination]. Haut Conseil a L'égalité entre les femmes et les hommes (in French). Archived from the original on January 7, 2013. "Maison de la justice et du droit" [House of Justice and Law] (in French). Archived from the original on April 12, 2013. "Association européenne contre les Violences faites aux Femmes au Travail" [European Association Against Violence Against Women at Work] (in French).
Sources: en.wikipedia.org
=== Sheep meat consumption === According to the OECD-FAO Agricultural Outlook for 2016, the top consumers of sheep meat in 2015 were as follows: EU countries are not individually surveyed in this list. Among EU nations, Greece is the per capita leader in consumption at 12.3 kg, with Cyprus following right after, while the UK's annual per capita lamb consumption is 4.7 kg. Outside of the OECD, the largest per capita consumer overall is Mongolia, with 45.1 kg.
The SI unit for pressure is the pascal (Pa), equal to one newton per square metre (N/m2, or kg·m−1·s−2). This name for the unit was added in 1971; before that, pressure in SI was expressed in newtons per square metre. Other units of pressure, such as pounds per square inch (lbf/in2) and bar, are also in common use. The CGS unit of pressure is the barye (Ba), equal to 1 dyn·cm−2, or 0.1 Pa. Pressure is sometimes expressed in grams-force or kilograms-force per square centimetre ("g/cm2" or "kg/cm2") and the like without properly identifying the force units. But using the names kilogram, gram, kilogram-force, or gram-force (or their symbols) as units of force is deprecated in SI. The technical atmosphere (symbol: at) is 1 kgf/cm2 (98.0665 kPa, or 14.223 psi). Pressure is related to energy density and may be expressed in units such as joules per cubic metre (J/m3, which is equal to Pa). Mathematically:
=== Rafts === The Lower Paleolithic Homo erectus possibly invented rafts (c. 840,000 – c. 800,000 BP) to travel over large bodies of water, which may have allowed a group of Homo erectus to reach the island of Flores and evolve into the small hominin Homo floresiensis. However, this hypothesis is disputed within the anthropological community. The possible use of rafts during the Lower Paleolithic may indicate that Lower Paleolithic hominins such as Homo erectus were more advanced than previously believed, and may have even spoken an early form of modern language. Supplementary evidence from Neanderthal and modern human sites located around the Mediterranean Sea, such as Coa de sa Multa (c. 300,000 BP), has also indicated that both Middle and Upper Paleolithic humans used rafts to travel over large bodies of water (i.e. the Mediterranean Sea) for the purpose of colonizing other bodies of land.
Emerging technologies are novel technologies whose development or practical applications are still largely unrealized. They include nanotechnology, biotechnology, robotics, 3D printing, and blockchains. In 2005, futurist Ray Kurzweil claimed the next technological revolution would rest upon advances in genetics, nanotechnology, and robotics, with robotics being the most impactful of the three technologies. Genetic engineering will allow far greater control over human biological nature through a process called directed evolution. Some thinkers believe that this may shatter humanity's sense of self, and they have urged for renewed public debate exploring the issue more thoroughly; others fear that directed evolution could lead to eugenics or extreme social inequality. Nanotechnology will grant the ability to manipulate matter "at the molecular and atomic scale", which could allow humanity to reshape itself and its environment in fundamental ways. Nanobots could be used within the human body to destroy cancer cells or form new body parts, blurring the line between biology and technology. Autonomous robots have undergone rapid progress, and they are expected to replace humans at many dangerous tasks, including search and rescue, bomb disposal, firefighting, and war. Estimates on the advent of artificial general intelligence vary, but half of machine learning experts surveyed in 2018 believe that AI will "accomplish every task better and more cheaply" than humans by 2063, and automate all human jobs by 2140.
Sources: en.wikipedia.org
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.
Hydrolysis, oxidation of susceptible residues, and aggregation all contribute, and their rates depend on pH, temperature, and concentration. Dissolved oxygen and trace metal ions accelerate oxidation. Keeping solutions cold, dilute, and free of unnecessary handling reduces these pathways.
Not always, because the value depends on the detection wavelength, the gradient, and how peak areas are integrated. A figure of ninety-eight percent from one laboratory may not mean the same as the same number from another. Comparing full chromatograms and mass spectra is more informative than comparing a single number.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.